In 624 patients with untreated advanced EGFR-mutated NSCLC, adding platinum–pemetrexed chemotherapy to aumolertinib lengthened median progression-free survival (28·9 vs 18·9 months; HR 0·47) but raised serious adverse events (36% vs 17%).
RCTn = 624
Li et al. Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial